Evidence map›Paper›PMID 37086853›Full record

ArticleVirologica Sinica2023

TRAF7 negatively regulates the RLR signaling pathway by facilitating the K48-linked ubiquitination of TBK1.

Jing-Ping Huang, Ya-Xian Yang, Tian Chen, Dan-Dan Wang, Jing Li, Liang-Guo Xu

Open access · hybridAbstract read
In one paragraph

Article in Virologica Sinica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. TheMicrobiology spectrum · 2024
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jing-Ping HuangCollege of Life Science, Jiangxi Normal University, Nanchang, 330022, China.
Ya-Xian YangCollege of Life Science, Jiangxi Normal University, Nanchang, 330022, China.
Tian ChenCollege of Life Science, Jiangxi Normal University, Nanchang, 330022, China.
Dan-Dan WangCollege of Life Science, Jiangxi Normal University, Nanchang, 330022, China.
Jing LiCollege of Life Science, Jiangxi Normal University, Nanchang, 330022, China.
Liang-Guo XuCollege of Life Science, Jiangxi Normal University, Nanchang, 330022, China. Electronic address: xul@jxnu.edu.cn.
Jiangxi Normal University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TANK-binding kinase 1 (TBK1) is a nodal protein involved in multiple signal transduction pathways. In RNA virus-mediated innate immunity, TBK1 is recruited to the prion-like platform formed by MAVS and subsequently activates the transcription factors IRF3/7 and NF-κB to produce type I interferon (IFN) and proinflammatory cytokines for the signaling cascade. In this study, TRAF7 was identified as a negative regulator of innate immune signaling. TRAF7 interacts with TBK1 and promotes K48-linked polyubiquitination and degradation of TBK1 through its RING domain, impairing the activation of IRF3 and the production of IFN-β. In addition, we found that the conserved cysteine residues at position 131 of TRAF7 are necessary for its function toward TBK1. Knockout of TRAF7 could facilitate the activation of IRF3 and increase the transcript levels of downstream antiviral genes. These data suggest that TRAF7 negatively regulates innate antiviral immunity by promoting the K48-linked ubiquitination of TBK1.

Indexed as

Interferon Type ISignal TransductionHEK293 CellsHumansImmunity, InnateProtein Serine-Threonine KinasesTumor Necrosis Factor Receptor-Associated Peptides and ProteinsUbiquitinationInterferon Type IProtein Serine-Threonine KinasesTBK1 protein, humanTRAF7 protein, humanTumor Necrosis Factor Receptor-Associated Peptides and ProteinsInnate immunityTANK-Binding kinase 1 (TBK1)TRAF7Type I interferonUbiquitination

Identifiers

PMID37086853
PMCPMC10311266
OpenAlexW4366606599

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.